Keywords
- Human Immunodeficiency Virus
- Human Immunodeficiency Virus Infection
- Nonnucleoside Reverse Transcriptase Inhibitor
- Viral Protease
- Human Immunodeficiency Virus Protease
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsBibliography
Arrighi JF, Poin M, Garcia E, Escola JM, et al. 2004. DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. JEM. 200:1279–1288. http:www.aidsinfo.nih.gov/guidelines.
Bang LM, Scott LJ. 2003. Emtricitabine: An antiretroviral agent for HIV infection. Drugs. 63:2413–2424.
Barreiro P, Rendon A, Rodriguqz-Novoa S, Soriano V. 2005. Atazanavir: the advent of a new generation of more convenient protease inhibitors. HIV Clin Trails. 6:51–60.
Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT. et al. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 220:868–871.
Berger EA, Murphy PM, Farber JM. 1999. Chemokine receptors as HIV coreceptors: Role in viral entry, tropism and disease. Annu Rev Immunol. 17:657–700.
Boshoff C, Weiss R. 2002. AIDS – related malignancies. Nat Rev Cancer 2:373–382.
Bradsley-Elliott A, Plosker GL. 2000. Nelfinavir: An update on its use in HIV infection. Drugs. 59:581–620.
Cao Y, Qin L, Zhang L, Safrit J, et al. 1995. Virologic and immunologic characterization of long term survivors of human immunodeficiency virus type 1 infection. NEJM. 332:201–208.
Chan D, Kim P. 1998. HIV entry and its inhibition. Cell. 93:681–684.
Chun TW, Engel D, Berrey MM, Shea T. et al. 1998. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV infection. Proc Natl. Acad Sci USA. 95:8869–8873
Clotet B, Bellos N, Molina JM, Cooper D, et al. 2007. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomized trials. Lancet. 369:1169–1178.
Coffin J, Haase A, Levy A, Montagnier L. et al. 1986. What to call the AIDS virus? Nature 321: 10–10.
Coffin JM. 1995. HIV population dynamics in vivo. Implications for genetic variation, pathogenesis and therapy. Science. 267:483–489.
Collier AC, Coombs RW, Schoenfeld DA, Bassett RL. et al. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS clinical trials group. N Engl J Med 334:1011–1017.
Connor EM, Sperling RS, Gelber R, Kiselev P, et al. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS clinical trials group protocol, 076 study group. NEJM. 331:1173–1180.
Coovadia H. 2004. Antiretroviral agents – how best to protect infants from HIV and save their mothers from AIDS. N Engl J Med 351:289–292.
Cvetkovic RS, Goa KL. 2003. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 63:769–802.
DeClercq E. 2003. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev. 16: 569–596.
Deeks SJ. 2006. Antiretroviral treatment of HIV infected adults. BMJ. 332:1489–1489.
DeLuca A, DiGiambenedetto S, Maida I, Nunez M, et al. 2004. Triple nucleoside regimens versus efavirenz. NEJM. 351:717–719.
Dolin R, Amato DA, Fischl MA, Pettinelli C, et al. 1995. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trial Group. Arch Int Med. 155:961–974.
Doyon L, Tremblay S, Bourgon L, Wardrop E, et al. 2005. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptide protease inhibitor tipranavir. Antiviral Res. 68:27–35.
Dudley MN. 1995. Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis. 171:S99–S112.
Ellis JM, Ross JW, Coleman CI. 2004. Fosamprenavir: A novel protease inhibitor and prodrug of amprenavir. Formulary. 19:151–160.
Embretson J, Zapancic M, Ribas JL, Burke A. et al. 1993. Massive convert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 362:359–362.
Fauci AS. 1996. Host factors and the pathogenesis of HIV-induced disease. Nature. 384:529–534.
Feldman C. 2005. Pneumonia associated with HIV infection. Curr Opin Infect Dis. 18:165–170.
Fischl MA, Stanley K, Collier AC, Arduino JM, et al. 1995. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials. Ann Int Med. 122:24–32.
Flexner C. 1998. HIV-protease inhibitors. N Engl J Med. 338:1281–1292.
Flexner C. 2000. Dual protease inhibitor therapy in HIV-infected patient: Pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol. 40:649–674.
Flexner C. 2005. Antiretroviral agents and treatment of HIV infection. In: Brunton LL, Ed. Goodman and Gilman’s, the Pharmacological Basis of Therapeutics. 11th Ed., The McGraw-Hill Companies.
Flexner C, Bate G, Kirkpatrick P. 2005. Tipranavir. Nat Rev Drug Discov. 4:955–956.
Furman PA, Fyfe JA, St. Clair MH, Weinhold K, et al. 1986. Phosphorylation of 3-azido-3 deoxythymidine and selective interaction of the 5’ triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA. 83:8333–8337.
Gallant JE, Gerondelis PZ, Wainberg MA, Shulman NS, et al. 2003. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: A clinical review of antiretroviral resistance. Antivir Ther. 8:489–506.
Gallant JE, DeJesus E, Arribas JR, Pozniak AL, et al. 2006. Tenofovir DF, Emtricitabine and Efavireuz vs. Zidovudine, Lamivudine and Efavirenz for HIV. NEJM. 354:251–260.
Gallo RC. 2005. The end or the beginning of the drive to an HIV preventive vaccine: a view from over 20 years. Lancet. 366:1894–1898.
Gao F, Bailes E, Robertson DL, Chen Y. et al. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes. Nature. 397:436–441.
Greene WC. 1991. The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med. 324:308–317.
Greene WC. 1993. AIDS and the immune system. Sci Am. 269:98–105.
Greene WC, Peterlin BM. 2002. Charting HIV’s remarkable voyage through the cell: Basic science as a passport for future therapy. Nat Med. 8:673–680.
Gulick RM, Mellors JW, Havilir D, Eron JJ, et al. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. NEJM. 337:734–739.
Gulick RM, Ribaudo HJ, Shikuma CM, Lustarten S, et al. 2004. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-infection. NEJM. 350:1850–1861.
Guss DA. 1994. The acquired immune deficiency syndrome: an overview for the emergency physician, Part I. J Emerg Med. 12:375–384.
Guss DA. 1994. The acquired immune deficiency syndrome: an overview for the emergency physician, Part II. J Emerg Med 12:491–497.
Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, et al. 1996. A trial comparing nucleoside monotherapy with combination therapy in HIV infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS clinical trials group study, 175 study team. NEJM. 335:1081–10990.
Hammer SM, Saag, MS, Schechter M, Montaner JSG, et al. 2006. Treatment for adult infection: 2006. Recommendations of the International AIDS Society-USA Panel. JAMA. 296:827–843.
Heeney JL, Dalgleish AG, Weiss RA. 2006. Origins of HIV and the evolution of resistance to AIDS. Science. 313: 462–466.
Hervey PS, Perry CM. 2000. Abacavir: A review of its clinical potential in patients with HIV infection. Drugs. 60:447–479.
Ho DD, Pomerantz RJ, Kaplan JC. 1987. Pathogenesis of infection with human immunodeficiency virus. N Engl J Med. 317:278–286.
Ho DD, Neumann AU, Perelson AS, Chen W. et al. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV infection. Nature. 373:123–126.
Hoxie JA, Alpers JD, Rackowski JL, Huebner K. et al. 1986. Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV. Science. 234:1123–1127.
Johnston MI, Fauci AS. 2007. An HIV vaccine – evolving concepts. N Engl J Med. 356: 2073–2081.
Kahn JO, Walker BD. 1998. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 331:33–39.
Kaplan SS, Hicks CB. 2005. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. J Antimicrob Chemother. 56:273–276.
Keet IP, Krol A, Klein MR, Veugelers P. et al. 1994. Characteristics of long term asymptomatic infection with human immunodeficiency virus type 1 in men with normal and low CD4+ cell counts. J Infect Dis. 169:1236–1243.
Kestler H, Kodama T, Ringler D, Marthas M. et al. 1990. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science. 248:1109–1112.
King JR, Acosta EP. 2006. Tipranavir: A novel nonpeptide protease inhibitor of HIV. Clin Pharmacokinet. 45:665–682.
Kinter A, McNally J, Riggin L, Jackson R, et al. 2007. Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals. Proc Natl Acad Sci USA. 104:3390–3395.
Kuritzkes DR. 2004. Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDs. 18:259–273.
Laessig KA, Lewis LL, Hammerstrom TS, Jenny-Avital ER, et al. 2006. Tenofir DF and emtricitabine vs. zidovudine and lamivudine. NEJM. 354:2506–2508.
Lalezari JP, Henry K, O’Hearn M, Montaner JSG, et al. 2003. Enfuvirtide on HIV fusion inhibitor, for drug resistant HIV infection in North and South America. NEJM. 348:2175–2185.
Lawn SD. 2004. AIDS in Africa. The impact of coinfections on the pathogenesis of HIV-1 infection. J Infect Dis. 48:1–12.
Lazzarin A, Clotet B, Cooper D, Reynes J, et al. 2003. Efficacy of enfuvirtide in patients infected with drug resistant HIV-1 in Europe and Australia. NEJM. 348:2186–2195.
Lee LM, Karon JM, Selik R, Neal JJ, et al. 2001. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States 1984–1997. JAMA, 285:1308–1315.
Letvin NL, Daniel MD, Sehgal PK, Desrosiers RC. et al. 1985. Induction of AIDS like disease in macaque monkeys with T-Cell tropic retrovirus STLV-III. Science. 230:71–73.
Levy JA. 1993. HIV pathogenesis and long term survival. AIDS. 7:1401–1410.
Levy JA. 1993. Pathogenesis of human immunodeficiency virus infection. Microbial Rev. 57:183–289.
Lohse N, Hansen ABE, Gerstoft J, Obel N. 2007. Improved survival in HIV-infected persons: Consequences and perspectives. J Antimicrob Chemother. 60:461–463.
Luft BJ, Chua A. 2000. Central nervous system Toxoplasmosis in HIV pathogenesis, diagnosis and therapy. Curr Infect Dis Rep. 2:358–362.
MacArthur RD. 2007. Darunavir: Promising initial results. Lancet. 369:1143–1144.
Manfredi R, Sabbatani S. 2006. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20). Curr Med Chem. 13:2369–2384.
Markel H. 2005. The search for effective HIV vaccines. N Engl J Med. 353:753–757.
Martin AM, Nolan D, Gaudieri S, Almeida CA, et al. 2004. Predisposition to abacavir hypersensitivity conferred by HLA-B∗57021 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA. 101:4180–4185.
Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, et al. 2003. Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. NEJM. 349:1036–1046.
Martinez-Picado J, DePasquale MP, Kartsonis N, Hanna GJ, et al. 2000. Antiretroviral resistance during successful therapy of human immunodeficiency virus type 1 infection. Proc Natl Acad Sci USA. 97:10948–10953.
Marx JL. 1982. New disease baffles medical community. Science. 217:618–621.
McLead GX, Hammer SM. 1992. Zidovudine: Five years later. Ann Intern Med. 117:487–501.
Mellors JW, Rinaldo CR, Gupta P, White RM, et al. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1167–1170.
Mellors JW, Munoz A, Giorgi JV, Margolick JB, et al. 1997. Plasma viral load and CD4+ lymphocytes as a prognostic markers of HIV infection. Ann Intern Med. 126:946–954.
Nilsson J, Boasso A, Velilla PA, Zhang R, et al. 2006. HIV-1 driven regulatory T cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood. 108: 3808–3817.
Oldfield V, Keating GM, Plosker G. 2005. Enfuvirtide: A review of its use in the management of HIV infection. Drugs. 65:1139–1160.
Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus. HIV outpatient study investigators. N Engl J Med. 338:853–860.
Pantaleo G, Demarest JF, Soudeyns H, Graziosi C, et al. 1994. Major expansion of CD8+ T Cells with a predominant V beta usage during the primary immune response to HIV. Nature. 370:463–467.
Perelson AS, Neumann AU, Markowitz M, Leonard JM, et al. 1996. HIV-1 dynamics in vivo: Virion clearance rate, infected cell-life span, and viral generation time. Science. 271: 1582–1586.
Perry CM, Faulds D. 1997. Lamivudine: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs. 53:657–680.
Perry CM, Noble S. 1998. Saquinavir soft-gel formulation: A Review of its use in patients with HIV infection. Drugs. 55:461–486.
Perry CM, Noble S. 1999. Didanosine: An updated review of its use in HIV infection. Drugs. 58:1099–1135.
Piscitelli SC, Gallicano KD. 2001. Interactions among drugs for HIV and opportunistic infection. NEJM. 344:984–996.
Plosker GL, Noble S. 1999. Indinavir: A review of its use in the management of HIV infection. Drugs. 58:1165–1203.
Pollard VW, Mallim MH. 1998. The HIV-1 Rev protein. Annu Rev Microbial. 52:491–532
Popovic M, Sarngadharan MG, Read E, Gallo RC. 1984. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-111) from patients with AIDS and pre AIDS. Science. 224:497–500.
Rivero A, Mira JA, Pineda JA. 2007. Liver toxicity induced by nono-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 59:342–346.
Sataszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, et al. 1999. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 team. NEJM. 341:1865–1873.
Shafer RW, Smeaton LM, Robbins GK, Gruttola V, et al. 2003. Comparison of four drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. NEJM. 349:2304–2315.
Shankar P, Russo M, Harnisch B, Patterson M, et al. 2000. Impaired function of circulating HIV-specific CD8+ T cells in chronic human immunodeficiency virus infection. Blood. 96: 3094–3101.
Spence RA, Kati WM, Anderson KS, Johnson KA. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science. 267:988–993.
Sperling RS, Shapirom DE, Coombsm RW, Todd JA, et al. 1996. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 335:1621–1629.
Steinbrook R. 2004. The AIDS epidemic in 2004. N Engl J Med. 351:115–117.
Swainston-Harrison T, Scott LJ. 2005. Atazanavir: A review of its use in the management of HIV infection. Drugs. 65:2309–2336.
Tonks A. 2007. Quest for the AIDS vaccine. BMJ. 334:1346–1348.
Wang JH. Janas AM, Oson WJ, Kewal Ramani VN, et al. 2007. CD4 coexpression regulates DC-SIGN-mediated transmission of human immunodeficiency virus type 1. J Virol. 81: 2497–2507.
Watts DH, Brown ZA, Tartaglione T, Burchett SK, et al. 1991. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis. 163:226–232.
Wei X, Ghosh SK, Taylor ME, Johnson VA, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:117–122.
Wire MB, Shelton MJ, Studenberg S. 2006. Forsamprenavir: Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 45:137–168.
Wood E, Hogg RS, Yip B, Harrigan PR, et al. 2003. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS. 17:711–720.
Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science. 280:1884–1888.
Young SD, Britcher SF, Tran LO, Payne LS, et al. 1995. Erfavirenz: A novel highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrog Agents Chemother. 39:2602–2605.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Khan, M.M. (2008). Acquired Immune Deficiency Syndrome. In: Immunopharmacology. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-77976-8_8
Download citation
DOI: https://doi.org/10.1007/978-0-387-77976-8_8
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-77975-1
Online ISBN: 978-0-387-77976-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)